Literature DB >> 2246955

Pelvic inflammatory disease.

H B Peterson1, E I Galaid, W Cates.   

Abstract

The costs of PID to both individuals and society are enormous. Although primary prevention of PID through control of lower genital tract infections is the most effective prevention strategy, early diagnosis and treatment of acute PID may minimize some of its serious sequelae. Although laparoscopy is helpful for establishing the diagnosis of salpingitis, other less invasive tests along with selected clinical criteria may also be useful. Treatment of PID, which is empiric and broad spectrum, is oriented toward polymicrobial PID. Whenever possible, women with PID should be hospitalized for parenteral therapy. The 1989 CDC STD treatment guidelines recommend two regimens for inpatient parenteral therapy: clindamycin/gentamicin and cefoxitin, or equivalent cephalosporin/doxycycline. Outpatient management of PID should be monitored closely; the CDC-recommended regimen includes use of intramuscular cephalosporins and oral doxycycline. Oral penicillins are no longer recommended.

Entities:  

Mesh:

Year:  1990        PMID: 2246955     DOI: 10.1016/s0025-7125(16)30497-7

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

Review 1.  Pelvic inflammatory disease. Current approaches.

Authors:  B Romanowski
Journal:  Can Fam Physician       Date:  1993-02       Impact factor: 3.275

2.  Diagnostic evaluation of pelvic inflammatory disease.

Authors:  J F Peipert; D E Soper
Journal:  Infect Dis Obstet Gynecol       Date:  1994

3.  Endometriosis is a risk factor for recurrent pelvic inflammatory disease after tubo-ovarian abscess surgery.

Authors:  Maria Zografou Themeli; Konstantinos Nirgianakis; Stephanie Neumann; Sara Imboden; M D Mueller
Journal:  Arch Gynecol Obstet       Date:  2022-08-29       Impact factor: 2.493

4.  Ampicillin/Sulbactam vs. Cefoxitin for the treatment of pelvic inflammatory disease.

Authors:  J G Jemsek; F Harrison
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.